Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
APOLLOHOSPNSE
MAXHEALTHNSE
MANIPALHOSNSE
ASTERDMNSE
FORTISNSE
MEDANTANSE
NHNSE
LALPATHLABNSE
KIMSNSE
AGARWALEYENSE
Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 13% | 12% | 11% | 12% |
| 14% | 12% | 28% | 4% |
| 13% | 3% | 14% | 28% |
| 24% | 22% | 23% | 22% |
Peer Comparison
Symbol
APOLLOHOSP
MAXHEALTH
MANIPALHOS
ASTERDM
FORTIS
MEDANTA
NH
LALPATHLAB
KIMS
AGARWALEYE
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 8,989 | ₹125737 Cr | 56.08 | 43.8 | 219.15 | ₹1942 Cr |
| 1,074.05 | ₹101061 Cr | 73.2 | 4.26 | 19.36 | ₹1442 Cr |
| 697.3 | ₹91656 Cr | 102.72 | 2.05 | 11.95 | ₹892 Cr |
| 744.6 | ₹64456 Cr | 136.94 | 3.01 | 9.46 | ₹388 Cr |
| 815.7 | ₹61061 Cr | 58.81 | 4.14 | 20.27 | ₹1042 Cr |
| 1,493.4 | ₹39740 Cr | 64.26 | 8.21 | 32.95 | ₹556 Cr |
| 1,911 | ₹38297 Cr | 44.59 | 14.73 | 71.14 | ₹806 Cr |
| 1,982 | ₹32935 Cr | 56.44 | 11.45 | 45.37 | ₹505 Cr |
| 776.8 | ₹32301 Cr | 152.07 | 1.79 | 14.23 | ₹241 Cr |
| 553.8 | ₹18439 Cr | 106.32 | 1.73 | 14.44 | ₹133 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹874 Cr | ₹798 Cr | ₹703 Cr | ₹660 Cr | ₹731 Cr | ₹670 Cr | ₹603 Cr | ₹597 Cr | ₹660 Cr | ₹602 Cr | ₹545 Cr | ₹539 Cr | ₹601 Cr | ₹541 Cr | ₹491 Cr | ₹489 Cr | ₹534 Cr | ₹503 Cr | ₹486 Cr | ₹497 Cr | ₹498 Cr | ₹607 Cr | ₹431 Cr | ₹452 Cr | ₹432 Cr | ₹266 Cr | ₹302 Cr | ₹328 Cr | ₹366 Cr | ₹335 Cr | ₹301 Cr | ₹293 Cr | ₹318 Cr | ₹292 Cr | ₹267 Cr | ₹263 Cr | ₹278 Cr | ₹249 Cr | ₹220 Cr | ₹208 Cr | ₹262 Cr | ₹223 Cr | ₹198 Cr | ₹189 Cr | ₹216 Cr | ₹189 Cr | ₹172 Cr | ₹156 Cr |
| ₹34 Cr | ₹32 Cr | ₹24 Cr | ₹24 Cr | ₹25 Cr | ₹28 Cr | ₹26 Cr | ₹25 Cr | ₹22 Cr | ₹21 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹14 Cr | ₹14 Cr | ₹11 Cr | ₹9 Cr | ₹8 Cr | ₹12 Cr | ₹12 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹11 Cr | ₹12 Cr | ₹14 Cr | ₹15 Cr | ₹14 Cr | ₹14 Cr | ₹12 Cr | ₹11 Cr | ₹9 Cr | ₹9 Cr | ₹7 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
| ₹908 Cr | ₹830 Cr | ₹727 Cr | ₹684 Cr | ₹755 Cr | ₹698 Cr | ₹628 Cr | ₹622 Cr | ₹682 Cr | ₹623 Cr | ₹564 Cr | ₹557 Cr | ₹619 Cr | ₹555 Cr | ₹505 Cr | ₹500 Cr | ₹543 Cr | ₹511 Cr | ₹498 Cr | ₹509 Cr | ₹513 Cr | ₹621 Cr | ₹445 Cr | ₹466 Cr | ₹445 Cr | ₹277 Cr | ₹314 Cr | ₹342 Cr | ₹380 Cr | ₹350 Cr | ₹315 Cr | ₹305 Cr | ₹328 Cr | ₹302 Cr | ₹276 Cr | ₹270 Cr | ₹286 Cr | ₹257 Cr | ₹227 Cr | ₹215 Cr | ₹269 Cr | ₹229 Cr | ₹204 Cr | ₹193 Cr | ₹221 Cr | ₹193 Cr | ₹175 Cr | ₹159 Cr |
| ₹641 Cr | ₹595 Cr | ₹561 Cr | ₹523 Cr | ₹547 Cr | ₹512 Cr | ₹470 Cr | ₹478 Cr | ₹493 Cr | ₹467 Cr | ₹437 Cr | ₹434 Cr | ₹459 Cr | ₹430 Cr | ₹413 Cr | ₹414 Cr | ₹429 Cr | ₹421 Cr | ₹402 Cr | ₹418 Cr | ₹377 Cr | ₹437 Cr | ₹329 Cr | ₹333 Cr | ₹324 Cr | ₹236 Cr | ₹264 Cr | ₹264 Cr | ₹274 Cr | ₹256 Cr | ₹245 Cr | ₹237 Cr | ₹240 Cr | ₹226 Cr | ₹214 Cr | ₹214 Cr | ₹208 Cr | ₹191 Cr | ₹178 Cr | ₹167 Cr | ₹189 Cr | ₹169 Cr | ₹151 Cr | ₹126 Cr | ₹187 Cr | ₹147 Cr | ₹136 Cr | ₹125 Cr |
| ₹315 Cr | ₹279 Cr | ₹211 Cr | ₹204 Cr | ₹249 Cr | ₹220 Cr | ₹195 Cr | ₹179 Cr | ₹224 Cr | ₹191 Cr | ₹163 Cr | ₹159 Cr | ₹196 Cr | ₹161 Cr | ₹130 Cr | ₹124 Cr | ₹153 Cr | ₹126 Cr | ₹133 Cr | ₹121 Cr | ₹156 Cr | ₹203 Cr | ₹136 Cr | ₹152 Cr | ₹140 Cr | ₹60 Cr | ₹69 Cr | ₹96 Cr | ₹124 Cr | ₹110 Cr | ₹80 Cr | ₹78 Cr | ₹98 Cr | ₹84 Cr | ₹73 Cr | ₹64 Cr | ₹86 Cr | ₹73 Cr | ₹57 Cr | ₹55 Cr | ₹87 Cr | ₹66 Cr | ₹60 Cr | ₹74 Cr | ₹41 Cr | ₹53 Cr | ₹47 Cr | ₹41 Cr |
| ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹9 Cr | ₹11 Cr | ₹9 Cr | ₹12 Cr | ₹9 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹10 L | ₹30 L | ₹20 L | ₹20 L | ₹20 L | ₹20 L | ₹30 L | ₹10 L | ₹20 L | ₹30 L | ₹10 L | ₹1 L | ₹27 L | ₹5 L | ₹15 L | ₹3 L | ₹37 L | ₹1 L |
| ₹261 Cr | ₹229 Cr | ₹160 Cr | ₹124 Cr | ₹204 Cr | ₹181 Cr | ₹153 Cr | ₹138 Cr | ₹183 Cr | ₹150 Cr | ₹120 Cr | ₹116 Cr | ₹152 Cr | ₹118 Cr | ₹83 Cr | ₹77 Cr | ₹103 Cr | ₹81 Cr | ₹84 Cr | ₹82 Cr | ₹131 Cr | ₹179 Cr | ₹111 Cr | ₹129 Cr | ₹117 Cr | ₹38 Cr | ₹45 Cr | ₹73 Cr | ₹102 Cr | ₹89 Cr | ₹69 Cr | ₹68 Cr | ₹88 Cr | ₹75 Cr | ₹62 Cr | ₹56 Cr | ₹78 Cr | ₹66 Cr | ₹49 Cr | ₹47 Cr | ₹80 Cr | ₹60 Cr | ₹53 Cr | ₹84 Cr | ₹17 Cr | ₹47 Cr | ₹39 Cr | ₹34 Cr |
| ₹194 Cr | ₹171 Cr | ₹132 Cr | ₹91 Cr | ₹152 Cr | ₹134 Cr | ₹156 Cr | ₹98 Cr | ₹131 Cr | ₹108 Cr | ₹86 Cr | ₹82 Cr | ₹111 Cr | ₹84 Cr | ₹57 Cr | ₹54 Cr | ₹72 Cr | ₹58 Cr | ₹62 Cr | ₹58 Cr | ₹96 Cr | ₹134 Cr | ₹85 Cr | ₹96 Cr | ₹87 Cr | ₹28 Cr | ₹33 Cr | ₹55 Cr | ₹81 Cr | ₹59 Cr | ₹47 Cr | ₹46 Cr | ₹57 Cr | ₹50 Cr | ₹40 Cr | ₹36 Cr | ₹51 Cr | ₹44 Cr | ₹32 Cr | ₹31 Cr | ₹53 Cr | ₹40 Cr | ₹35 Cr | ₹61 Cr | ₹6 Cr | ₹31 Cr | ₹29 Cr | ₹23 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Trade Payables
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹168 Cr | ₹84 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹83 Cr | ₹81 Cr | ₹80 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| ₹66 Cr | ₹57 Cr | ₹51 Cr | ₹58 Cr | ₹58 Cr | ₹40 Cr | ₹33 Cr | ₹28 Cr | ₹18 Cr | ₹9 Cr | ₹73 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2275 Cr | ₹2032 Cr | ₹1715 Cr | ₹1525 Cr | ₹1360 Cr | ₹1122 Cr | ₹917 Cr | ₹834 Cr | ₹687 Cr | ₹504 Cr | ₹424 Cr | ₹260 Cr | ₹151 Cr | ₹157 Cr | ₹111 Cr | ₹88 Cr |
| ₹2275 Cr | ₹2032 Cr | ₹1715 Cr | ₹1525 Cr | ₹1360 Cr | ₹1122 Cr | ₹917 Cr | ₹834 Cr | ₹687 Cr | ₹504 Cr | ₹424 Cr | ₹260 Cr | ₹151 Cr | ₹157 Cr | ₹111 Cr | ₹88 Cr |
| ₹2508 Cr | ₹2173 Cr | ₹1849 Cr | ₹1666 Cr | ₹1502 Cr | ₹1245 Cr | ₹1033 Cr | ₹945 Cr | ₹788 Cr | ₹596 Cr | ₹507 Cr | ₹341 Cr | ₹231 Cr | ₹162 Cr | ₹116 Cr | ₹93 Cr |
| ₹33 Cr | ₹34 Cr | ₹36 Cr | ₹33 Cr | ₹35 Cr | ₹31 Cr | ₹21 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹65 L |
| ₹0 | ₹0 | ₹0 | ₹83 Cr | ₹167 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹4 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹13 L | ₹12 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| -₹82 Cr | -₹83 Cr | -₹42 Cr | -₹37 Cr | -₹33 Cr | -₹27 Cr | -₹23 Cr | -₹21 Cr | -₹17 Cr | -₹14 Cr | -₹12 Cr | -₹25 Cr | -₹20 Cr | -₹13 Cr | -₹3 Cr | -₹2 Cr |
| ₹145 Cr | ₹103 Cr | ₹103 Cr | ₹130 Cr | ₹139 Cr | ₹110 Cr | ₹93 Cr | ₹1 Cr | ₹8 Cr | ₹7 Cr | ₹14 Cr | ₹12 Cr | ₹14 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹10 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr |
| ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹20 L | ₹21 L | ₹26 L | ₹5 L | ₹2 Cr | ₹1 Cr |
| ₹67 Cr | ₹21 Cr | ₹62 Cr | ₹176 Cr | ₹273 Cr | ₹83 Cr | ₹70 Cr | -₹20 Cr | -₹9 Cr | -₹6 Cr | ₹12 Cr | -₹5 Cr | ₹1 Cr | ₹3 Cr | ₹8 Cr | ₹10 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹181 Cr | ₹167 Cr | ₹187 Cr | ₹156 Cr | ₹147 Cr | ₹144 Cr | ₹118 Cr | ₹80 Cr | ₹65 Cr | ₹52 Cr | ₹42 Cr | ₹34 Cr | ₹33 Cr | ₹31 Cr | ₹23 Cr | ₹17 Cr |
| ₹189 Cr | ₹186 Cr | ₹227 Cr | ₹214 Cr | ₹227 Cr | ₹108 Cr | ₹94 Cr | ₹41 Cr | ₹40 Cr | ₹25 Cr | ₹18 Cr | ₹59 Cr | ₹50 Cr | ₹42 Cr | ₹7 Cr | ₹21 Cr |
| ₹0 | ₹0 | ₹0 | ₹70 Cr | ₹95 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹87 L | ₹37 L | ₹1 L | ₹14 Cr |
| ₹81 Cr | ₹49 Cr | ₹50 Cr | ₹30 Cr | ₹30 Cr | ₹22 Cr | ₹16 Cr | ₹18 Cr | ₹10 Cr | ₹7 Cr | ₹31 Cr | ₹19 Cr | ₹13 Cr | ₹15 Cr | ₹19 Cr | ₹12 Cr |
| ₹451 Cr | ₹402 Cr | ₹464 Cr | ₹470 Cr | ₹500 Cr | ₹274 Cr | ₹227 Cr | ₹138 Cr | ₹116 Cr | ₹85 Cr | ₹91 Cr | ₹112 Cr | ₹97 Cr | ₹89 Cr | ₹49 Cr | ₹64 Cr |
| ₹3058 Cr | ₹2630 Cr | ₹2411 Cr | ₹2345 Cr | ₹2310 Cr | ₹1633 Cr | ₹1351 Cr | ₹1069 Cr | ₹899 Cr | ₹676 Cr | ₹613 Cr | ₹450 Cr | ₹332 Cr | ₹256 Cr | ₹174 Cr | ₹167 Cr |
| ₹17 Cr | ₹11 Cr | ₹10 Cr | ₹14 Cr | ₹13 Cr | ₹10 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹90 L |
| ₹0 | ₹0 | ₹83 Cr | ₹237 Cr | ₹346 Cr | ₹12 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹87 L | ₹37 L | ₹1 L | ₹20 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹2146 Cr | ₹1904 Cr | ₹1828 Cr | ₹1807 Cr | ₹1726 Cr | ₹684 Cr | ₹574 Cr | ₹302 Cr | ₹264 Cr | ₹180 Cr | ₹336 Cr | ₹295 Cr | ₹258 Cr | ₹218 Cr | ₹175 Cr | ₹161 Cr |
| ₹923 Cr | ₹769 Cr | ₹635 Cr | ₹502 Cr | ₹357 Cr | ₹236 Cr | ₹161 Cr | ₹93 Cr | ₹56 Cr | ₹28 Cr | ₹170 Cr | ₹145 Cr | ₹119 Cr | ₹91 Cr | ₹67 Cr | ₹49 Cr |
| ₹1224 Cr | ₹1135 Cr | ₹1194 Cr | ₹1305 Cr | ₹1369 Cr | ₹447 Cr | ₹413 Cr | ₹209 Cr | ₹208 Cr | ₹152 Cr | ₹166 Cr | ₹150 Cr | ₹140 Cr | ₹127 Cr | ₹108 Cr | ₹112 Cr |
| ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹14 Cr | ₹6 Cr | ₹10 Cr | ₹3 Cr | ₹10 Cr | ₹16 Cr | ₹4 Cr | ₹95 L | ₹17 L | ₹52 L | ₹40 L | ₹3 L |
| ₹33 Cr | ₹27 Cr | ₹31 Cr | ₹35 Cr | ₹40 Cr | ₹27 Cr | ₹20 Cr | ₹17 Cr | ₹16 Cr | ₹18 Cr | ₹16 Cr | ₹14 Cr | ₹19 Cr | ₹9 Cr | ₹9 Cr | ₹8 Cr |
| ₹196 Cr | ₹68 Cr | ₹20 Cr | ₹27 Cr | ₹11 Cr | ₹4 Cr | ₹14 Cr | ₹26 Cr | ₹42 Cr | ₹22 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹9 Cr | ₹3 Cr |
| ₹1492 Cr | ₹1267 Cr | ₹1284 Cr | ₹1372 Cr | ₹1435 Cr | ₹488 Cr | ₹459 Cr | ₹255 Cr | ₹276 Cr | ₹210 Cr | ₹189 Cr | ₹168 Cr | ₹162 Cr | ₹139 Cr | ₹132 Cr | ₹123 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹423 Cr | ₹327 Cr | ₹114 Cr | ₹150 Cr | ₹65 Cr | ₹59 Cr | ₹164 Cr | ₹185 Cr | ₹145 Cr | ₹106 Cr | ₹64 Cr | ₹38 Cr | ₹9 Cr | ₹55 Cr | ₹5 Cr | ₹1 Cr |
| ₹44 Cr | ₹36 Cr | ₹37 Cr | ₹34 Cr | ₹53 Cr | ₹43 Cr | ₹57 Cr | ₹29 Cr | ₹27 Cr | ₹18 Cr | ₹15 Cr | ₹14 Cr | ₹12 Cr | ₹9 Cr | ₹6 Cr | ₹8 Cr |
| ₹111 Cr | ₹88 Cr | ₹77 Cr | ₹71 Cr | ₹85 Cr | ₹67 Cr | ₹51 Cr | ₹53 Cr | ₹41 Cr | ₹42 Cr | ₹36 Cr | ₹31 Cr | ₹25 Cr | ₹20 Cr | ₹14 Cr | ₹10 Cr |
| ₹910 Cr | ₹839 Cr | ₹830 Cr | ₹665 Cr | ₹618 Cr | ₹926 Cr | ₹569 Cr | ₹490 Cr | ₹314 Cr | ₹240 Cr | ₹210 Cr | ₹148 Cr | ₹106 Cr | ₹21 Cr | ₹13 Cr | ₹22 Cr |
| ₹53 Cr | ₹51 Cr | ₹48 Cr | ₹34 Cr | ₹34 Cr | ₹32 Cr | ₹30 Cr | ₹24 Cr | ₹15 Cr | ₹13 Cr | ₹10 Cr | ₹7 Cr | ₹6 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹26 Cr | ₹23 Cr | ₹20 Cr | ₹19 Cr | ₹20 Cr | ₹19 Cr | ₹21 Cr | ₹32 Cr | ₹81 Cr | ₹49 Cr | ₹89 Cr | ₹43 Cr | ₹13 Cr | ₹10 Cr | ₹1 Cr | ₹1 Cr |
| ₹1566 Cr | ₹1364 Cr | ₹1127 Cr | ₹973 Cr | ₹875 Cr | ₹1145 Cr | ₹893 Cr | ₹814 Cr | ₹623 Cr | ₹467 Cr | ₹424 Cr | ₹282 Cr | ₹170 Cr | ₹117 Cr | ₹42 Cr | ₹44 Cr |
| ₹1116 Cr | ₹961 Cr | ₹663 Cr | ₹503 Cr | ₹375 Cr | ₹871 Cr | ₹665 Cr | ₹675 Cr | ₹507 Cr | ₹382 Cr | ₹333 Cr | ₹170 Cr | ₹73 Cr | ₹28 Cr | -₹7 Cr | -₹20 Cr |
| ₹3058 Cr | ₹2630 Cr | ₹2411 Cr | ₹2345 Cr | ₹2310 Cr | ₹1633 Cr | ₹1351 Cr | ₹1069 Cr | ₹899 Cr | ₹676 Cr | ₹613 Cr | ₹450 Cr | ₹332 Cr | ₹256 Cr | ₹174 Cr | ₹167 Cr |
| ₹146 | ₹253 | ₹215 | ₹193 | ₹173 | ₹145 | ₹120 | ₹110 | ₹92 | ₹71 | ₹61 | ₹58 | ₹382 | ₹4,781 | ₹3,408 | ₹2,688 |
| ₹146 | ₹127 | ₹108 | ₹96 | ₹173 | ₹145 | ₹120 | ₹110 | ₹92 | ₹71 | ₹61 | ₹58 | ₹38 | ₹30 | ₹21 | ₹17 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹669 Cr | ₹625 Cr | ₹505 Cr | ₹344 Cr | ₹475 Cr | ₹394 Cr | ₹311 Cr | ₹301 Cr | ₹261 Cr | ₹156 Cr | ₹201 Cr | ₹140 Cr | ₹119 Cr | ₹80 Cr | ₹66 Cr | ₹45 Cr |
| ₹115 Cr | ₹107 Cr | ₹126 Cr | ₹183 Cr | ₹118 Cr | ₹69 Cr | ₹55 Cr | ₹13 Cr | ₹21 Cr | ₹94 Cr | ₹8 Cr | ₹44 Cr | ₹38 Cr | ₹44 Cr | ₹22 Cr | ₹13 Cr |
| ₹27 Cr | ₹1 Cr | ₹36 Cr | ₹35 Cr | -₹17 Cr | ₹37 Cr | ₹12 Cr | ₹9 Cr | ₹9 Cr | -₹8 Cr | ₹19 Cr | -₹8 Cr | -₹9 Cr | -₹3 Cr | -₹4 L | ₹18 L |
| ₹811 Cr | ₹733 Cr | ₹667 Cr | ₹562 Cr | ₹577 Cr | ₹500 Cr | ₹377 Cr | ₹323 Cr | ₹291 Cr | ₹242 Cr | ₹227 Cr | ₹175 Cr | ₹148 Cr | ₹122 Cr | ₹89 Cr | ₹58 Cr |
| ₹636 Cr | ₹569 Cr | ₹535 Cr | ₹456 Cr | ₹447 Cr | ₹398 Cr | ₹284 Cr | ₹219 Cr | ₹197 Cr | ₹171 Cr | ₹159 Cr | ₹122 Cr | ₹98 Cr | ₹88 Cr | ₹68 Cr | ₹42 Cr |
| -₹422 Cr | -₹303 Cr | -₹24 Cr | -₹287 Cr | -₹449 Cr | -₹212 Cr | -₹26 Cr | -₹100 Cr | -₹172 Cr | -₹137 Cr | -₹163 Cr | -₹113 Cr | -₹90 Cr | -₹65 Cr | -₹26 Cr | -₹19 Cr |
| -₹264 Cr | -₹334 Cr | -₹414 Cr | -₹283 Cr | ₹136 Cr | -₹139 Cr | -₹190 Cr | -₹55 Cr | ₹13 Cr | -₹32 Cr | ₹36 L | -₹80 L | -₹10 Cr | -₹15 Cr | -₹38 Cr | -₹22 Cr |
| -₹50 Cr | -₹68 Cr | ₹97 Cr | -₹114 Cr | ₹134 Cr | ₹48 Cr | ₹67 Cr | ₹64 Cr | ₹37 Cr | ₹2 Cr | -₹5 Cr | ₹8 Cr | -₹2 Cr | ₹8 Cr | ₹4 Cr | ₹1 Cr |
| ₹293 Cr | ₹361 Cr | ₹264 Cr | ₹378 Cr | ₹244 Cr | ₹197 Cr | ₹129 Cr | ₹66 Cr | ₹29 Cr | ₹27 Cr | ₹23 Cr | ₹16 Cr | ₹17 Cr | ₹8 Cr | ₹4 Cr | ₹3 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹40 L | ₹1 Cr | ₹0 | ₹16 L |
| ₹243 Cr | ₹293 Cr | ₹361 Cr | ₹264 Cr | ₹378 Cr | ₹244 Cr | ₹197 Cr | ₹129 Cr | ₹66 Cr | ₹29 Cr | ₹19 Cr | ₹23 Cr | ₹16 Cr | ₹17 Cr | ₹8 Cr | ₹4 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 2 out of 9 oscillators
RSI
57.81Buy
STOCH %K
63.83Neutral
MACD Level(12,26)
20.37Buy
Ultimate Oscillator
47.38Sell
Aroon Oscillator
22.00Sell
BOP
0.63Buy
CCI
43.61Neutral
Williams %R
-36.17Neutral
Momentum
118.80Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
1984.53Buy
SMA 9
1995.83Buy
EMA 21
1966.13Buy
SMA 21
1956.50Buy
EMA 50
1933.28Buy
SMA 50
1936.16Buy
EMA 200
1756.27Buy
SMA 200
1680.96Buy
WMA 20
1981.92Buy
Pivot
Pivot
Classic
Resistance 5
2085.50
Resistance 4
2055.00
Resistance 3
2024.50
Resistance 2
1994.00
Resistance 1
1978.60
Pivot
1963.50
Support 1
1948.10
Support 2
1933.00
Support 3
1902.50
Support 4
1872.00
Support 5
1841.50
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 52.93% | 53.19% | 53.21% | 53.21% | 53.21% | 53.79% |
| 18.73% | 17.35% | 17.18% | 20.29% | 21.86% | 21.69% |
| 2.75% | 2.66% | 2.61% | 2.22% | 2.18% | 2.45% |
| 18.68% | 18.79% | 18.62% | 16.84% | 15.90% | 15.04% |
| 6.91% | 8.01% | 8.38% | 7.44% | 6.85% | 7.03% |
Bulk & block deals
Name
Goldman Sachs Bank Europe Se - Odi
Goldman Sachs (Singapore) Pte - Odi
Multi-Manager Icvc
Ishares India Sc Mauritius Company
Ishares Msci India Small-Cap Etf
Ishares Core Emerging Markets Mauritius Co
Ishares Core Msci Emerging Markets Etf
Ishares Core Msci Emerging Markets Etf
Ishares Msci India Small-Cap Etf
Ishares India Sc Mauritius Company
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 20 Oct 2025 | Purchase | 10.56 Cr | ₹3,160 | 33.41 K | Block | 0.039885 | NSE |
| 20 Oct 2025 | Sell | 10.56 Cr | ₹3,160 | 33.41 K | Block | 0.039885 | NSE |
| 06 Jan 2025 | Sell | 130.36 Cr | ₹2,997.11 | 4.35 L | Bulk | 0.519177 | NSE |
| 25 Oct 2022 | Sell | 3.30 Cr | ₹2,550.90 | 12.95 K | Block | 0.007715 | BSE |
| 25 Oct 2022 | Purchase | 3.30 Cr | ₹2,550.90 | 12.95 K | Block | 0.007715 | BSE |
| 25 Oct 2022 | Sell | 17.68 Cr | ₹2,550.90 | 69.32 K | Block | 0.041298 | BSE |
| 25 Oct 2022 | Purchase | 17.68 Cr | ₹2,550.90 | 69.32 K | Block | 0.041298 | BSE |
| 17 Oct 2022 | Purchase | 16.46 Cr | ₹2,377.50 | 69.25 K | Block | 0.041257 | BSE |
| 17 Oct 2022 | Purchase | 3.08 Cr | ₹2,377.50 | 12.93 K | Block | 0.007706 | BSE |
| 17 Oct 2022 | Sell | 3.08 Cr | ₹2,377.50 | 12.93 K | Block | 0.007706 | BSE |
Insider trading & SAST
Client name
Abhishek Maini
Dr. Lal Pathlabs Employee Welfare Trust
Munender Soperna
Abhishek Maini
Mrinal Kapoor
Dr. Lal Pathlabs Employee Welfare Trust
Sanjay Kulshreshtha
Mrinal Kapoor
Sanjay Kulshreshtha
Dr. Lal Pathlabs Employee Welfare Trust
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2026 | Designated Person | Disposal | 0.000447 | 0 | 14.70 L | ₹1,960 | 750 | 29 Sep 2026 | Market Sale | 0 | Insider Trading | — | Equity |
| 30 Sep 2026 | Other | Disposal | 0.002413 | 0.41 | 39.10 L | ₹965.36 | 4.05 K | 28 Sep 2026 - 30 Sep 2026 | ESOP | 6,91,886 | Insider Trading | — | Equity |
| 30 Sep 2026 | Designated Person | Acquisition | 0.001251 | 0.02 | 20.27 L | ₹965.03 | 2.10 K | 28 Sep 2026 | ESOP | 34,020 | Insider Trading | — | Equity |
| 30 Sep 2026 | Designated Person | Acquisition | 0.000447 | 0 | 8.56 L | ₹1,141.20 | 750 | 28 Sep 2026 | ESOP | 750 | Insider Trading | — | Equity |
| 25 Sep 2026 | Designated Person | Acquisition | 0.001192 | 0 | 24.52 L | ₹1,225.98 | 2 K | 23 Sep 2026 | ESOP | 2,000 | Insider Trading | — | Equity |
| 25 Sep 2026 | Other | Disposal | 0.001787 | 0.41 | 36.47 L | ₹1,215.78 | 3 K | 23 Sep 2026 | ESOP | 6,95,936 | Insider Trading | — | Equity |
| 25 Sep 2026 | Designated Person | Disposal | 0.000894 | 0 | 29.70 L | ₹1,980 | 1.50 K | 25 Sep 2026 | Market Sale | 3,500 | Insider Trading | — | Equity |
| 25 Sep 2026 | Designated Person | Disposal | 0.001192 | 0 | 39.02 L | ₹1,951 | 2 K | 25 Sep 2026 | Market Sale | 0 | Insider Trading | — | Equity |
| 25 Sep 2026 | Designated Person | Acquisition | 0.000596 | 0 | 11.95 L | ₹1,195.38 | 1 K | 23 Sep 2026 | ESOP | 5,000 | Insider Trading | — | Equity |
| 21 Sep 2026 | Other | Disposal | 0.0014 | 0.42 | 25.49 L | ₹1,084.57 | 2.35 K | 15 Sep 2026 | ESOP | 6,98,936 | Insider Trading | — | Equity |
Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad
Corporate Actions
Date
Type
Details
Company details
Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Dr. Lal Pathlabs Share Price
2006.00+0.00 (+2.18%)
+27.68% past 1 Year
News
1 of 20
Stock NewsLALPATHLAB5 Nov 2026
Nomura maintained its Buy rating on Dr Lal PathLabs with a target price of Rs 2280. The company delivered a strong Q2 FY27, supported by broad-based volume growth and improved realisations, resulting in an earnings beat and EBITDA margins reaching a multi-quarter high.
Nomura expects FY27 revenue growth of 18.7% and an EBITDA margin of 29.4%, ahead of management guidance of 27% to 28%. The forecast is supported by strong first-half FY27 performance. Higher volumes, improved realisations and operating leverage could support earnings growth and profitability, although the report does not provide details of any corporate action or stock price movement.
The development is relevant to the healthcare diagnostics sector and provides a positive earnings outlook for Dr Lal PathLabs.
Dr. Lal Pathlabs reports Profit after tax of 179.70 Crores, in the September 2026 quarter
ResultLALPATHLAB4 Nov 2026
NULL
Lal PathLabs Reports Stronger Q2 EBITDA And Improved Operating Margin
ResultLALPATHLAB4 Nov 2026
Dr Lal PathLabs reported Q2 EBITDA of Rs 280 crores, rising from Rs 224 crores year on year, representing growth of approximately 25%. EBITDA margin improved to 32.05% from 30.7% in the corresponding quarter, indicating stronger operating profitability. Revenue and PAT figures, along with quarter-on-quarter comparisons, were not provided in the available update and have therefore not been included. The result reflects improved earnings before interest, taxes, depreciation and amortisation and expansion in operating margin. Dr Lal PathLabs operates in the healthcare and diagnostic services sector. The company is listed on NSE under the symbol LALPATHLAB, with ISIN INE600L01024.
Lal PathLabs Reports Strong Second Quarter Revenue Growth Year On Year
ResultLALPATHLAB4 Nov 2026
Dr Lal PathLabs reported second-quarter revenue of Rs 870.00 crores, compared with Rs 730.00 crores in the corresponding quarter a year earlier, representing year-on-year growth of 19.18%. EBITDA and PAT figures, margin trends, sequential performance, management commentary, consensus estimates, and market reaction were not provided. The reported revenue growth indicates stronger operating scale for the diagnostic services company, but the overall earnings assessment remains limited without profitability and margin data.
Lal PathLabs Reports Strong Second Quarter Net Profit Growth
ResultLALPATHLAB4 Nov 2026
Dr. Lal PathLabs reported consolidated second-quarter net profit of Rs 190.00 crores, compared with Rs 151.00 crores in the corresponding period a year earlier, representing year-on-year growth of approximately 25.8 percent. Revenue from operations, EBITDA, operating margin, net margin, quarter-on-quarter performance and street expectations were not provided in the available information.
The reported increase in consolidated profit indicates improved profitability during the quarter. No management guidance or market reaction was available.
Dr Lal PathLabs Subsidiary Acquires Final Stake In CentraPath Labs
Stock NewsLALPATHLAB13 Oct 2026
PathLabs Unifiers Private Limited, a subsidiary of Dr. Lal PathLabs, has acquired the remaining 30% equity stake in CentraPath Labs at Rs 1,608.35 per share. Following the transaction, CentraPath Labs has become wholly owned by PathLabs Unifiers and a step-down subsidiary of Dr. Lal PathLabs.
The acquisition consolidates Dr. Lal PathLabs ownership of CentraPath Labs and may support greater operational control, business integration and retention of the subsidiarys future earnings. The disclosed information does not specify the total transaction value, earnings contribution or immediate stock price impact. The development is a routine corporate action with limited near-term effect on consolidated financial performance.
Dr Lal PathLabs Completes Acquisition Of 80 Percent Stake In Ghana Healthcare Company
Stock NewsLALPATHLAB26 Sept 2026
Dr. Lal PathLabs has completed the acquisition of an 80 percent stake in Sunshine Healthcare Limited, Ghana. Following completion of the transaction, Sunshine Healthcare Limited has become a step-down subsidiary of Dr. Lal PathLabs. The acquisition expands the company’s presence in the African healthcare and diagnostics market and may support international business growth and market diversification. The transaction value, funding structure, earnings contribution and operating metrics were not provided in the available information.
Dr Lal PathLabs to acquire controlling stake in SN Genelab for Rs 168 crores
Stock NewsLALPATHLAB24 Sept 2026
Dr Lal PathLabs will acquire a 70% stake in SN Genelab for consideration of up to Rs 168 crores, along with an earn-out payment of up to Rs 31.5 crores. The transaction will give Dr Lal PathLabs a controlling interest in SN Genelab and expand its diagnostic services and market presence.
The acquisition is expected to support revenue growth and strengthen the company’s laboratory network, although the final financial impact will depend on SN Genelab’s operating performance and the earn-out conditions. The transaction value represents a material deployment of capital, but no details on funding, profitability, or leverage impact were provided.
Dr Lal Pathlabs forms overseas subsidiary in Tashkent, Uzbekistan market entry
Stock NewsLALPATHLAB19 Aug 2026
Dr Lal Pathlabs Ltd has announced the launch of a new subsidiary, Dr. Lal Pathlabs Indomed, in Tashkent, Uzbekistan. The move marks a strategic step in the company’s international expansion beyond its core Indian diagnostics business and reflects management’s intent to tap emerging demand for organised pathology and diagnostic services in Central Asia. By choosing Tashkent, the largest city and economic hub of Uzbekistan, the company positions itself to serve a sizeable urban population, potentially including both retail patients and institutional healthcare clients. The subsidiary structure suggests a long-term commitment to building a local presence, complying with regional regulations, and tailoring its service offerings to that market’s healthcare ecosystem.
From an earnings perspective, the venture is likely to be modest in scale initially, with near-term financial impact expected to be limited as the business ramps up and incurs start-up and compliance costs. However, successful execution could diversify revenue streams over time, reduce reliance on the domestic market, and enhance the company’s brand as a regional diagnostics player. The expansion may also provide operational benefits such as broader test volumes, better utilisation of central lab infrastructure, and scope for knowledge transfer across geographies. Investors will watch subsequent disclosures for details on capital outlay, timelines to breakeven, and any partnership arrangements with local healthcare providers. In the absence of specific quantified guidance on investment size, targeted market share or expected revenue contribution, the development is best viewed as a strategic, growth-oriented initiative rather than a near-term driver of profitability or leverage metrics.
Dr Lal Pathlabs signals stronger mid-teen growth outlook and margin upside
Stock NewsLALPATHLAB27 Jul 2026
Dr Lal Pathlabs has indicated a more optimistic revenue trajectory, hinting that overall growth could move into the mid-teen range, compared with the earlier guidance that was broadly aligned to 6-7 percent patient volume growth. The commentary suggests that the company expects operating leverage and business mix to support higher top line expansion once the upcoming Q2 results provide clearer visibility. Management expectations around profitability also appear constructive, with the current Ebitda margin estimate of about 27 to 28 percent seen as having potential upside after Q2, subject to actual performance and operating conditions.
Importantly, Dr Lal Pathlabs plans to reinvest any incremental margin gains back into the business to fund future expansion. This likely includes spending on network scale-up, technology, and capabilities that can deepen its presence in key geographies and support long-term market share gains in the diagnostic services space. Such a reinvestment-led approach indicates a focus on sustainable growth over near-term cash extraction, which can influence the company’s earnings profile by balancing margin improvement with higher growth-related operating costs.
From an equity market perspective, an implied shift from single-digit to mid-teen revenue growth expectations, combined with a possibility of stronger Ebitda margins, is generally supportive for earnings upgrades and valuation comfort. The actual impact on the stock will depend on whether Q2 results validate this improved outlook and how quickly expansion plans translate into higher volumes and realizations. There is no indication in the context of any immediate corporate actions such as stake sales, buybacks, or large debt-funded capex, so leverage risk does not appear to be a focal issue in the current narrative. Overall, the news flow is centered on guidance and strategic capital allocation rather than regulatory developments or macro-driven changes.
Dr Lal Pathlabs plans aggressive capex for new labs and radiology expansion
Stock NewsLALPATHLAB27 Jul 2026
Dr Lal Pathlabs has outlined an expansion strategy focused on strengthening its diagnostics footprint through a mix of organic growth and mergers and acquisitions. The company aims to open around 12-15 new laboratories during the current year, indicating a calibrated push to deepen its presence in existing markets and selectively enter new geographies. In addition, the company plans to set up 3-4 radiology centers, with some pilot facilities proposed beyond the Delhi NCR region. This suggests a strategic intent to diversify its service mix beyond traditional pathology and to test scalable radiology formats in newer catchment areas.
The planned capital expenditure for the current year and the next is estimated at approximately Rs 140-150 crores. This capex outlay is primarily earmarked for mergers and acquisitions and for developing advanced radiology centers, indicating a bias towards higher-value, technology-intensive offerings rather than basic infrastructure alone. A focused deployment of capex into M&A could help Dr Lal Pathlabs consolidate smaller regional players, accelerate network expansion, and potentially improve economies of scale. Meanwhile, investments in advanced radiology centers are likely to enhance the company’s comprehensive diagnostics portfolio, support higher realization per patient, and strengthen competitive positioning against integrated diagnostic and hospital chains.
From an earnings perspective, the expansion of labs and radiology centers, if executed efficiently, can support volume growth and improve revenue mix over the medium term, though near-term margins may reflect the impact of ramp-up costs and depreciation from the new assets. Leverage levels will depend on the funding mix for this Rs 140-150 crores capex, but such a quantum appears manageable for a leading diagnostics franchise. Overall, the planned network and radiology expansion underscores management’s confidence in sustained demand for organized diagnostics and its intention to capture higher market share in both pathology and imaging services.
Dr Lal PathLabs sees mid teens FY revenue growth after strong Q1
Stock NewsLALPATHLAB27 Jul 2026
Dr Lal PathLabs said its international business is expected to stay below 5% growth for the next 2 to 3 years, with management treating it as a long term project. The company also indicated that a strong first quarter has improved its outlook for the full financial year, and it now expects revenue growth in the mid teens rather than early teens.
The update points to better domestic momentum supporting overall growth, while the international business remains a relatively small and longer gestation opportunity. For investors, the key monitorable is whether the stronger quarterly trend sustains and translates into higher annual revenue without pressure on margins or operating costs.
Dr Lal Pathlabs announces Rs 5 per share dividend approval
ResultLALPATHLAB24 Jul 2026
Dr Lal Pathlabs has approved a dividend of Rs 5 per share, indicating the company’s continued emphasis on shareholder returns within its overall capital allocation framework. The announcement pertains specifically to the equity shares of the company and reflects management’s confidence in its cash generation and balance sheet strength. While the detailed quarterly or annual financial results, including revenue, EBITDA, and PAT figures, are not provided in the available context, the decision to declare a dividend suggests that the board considers the company’s operating performance and liquidity position sufficiently robust to support cash payouts alongside ongoing business investments.
In the absence of specific financial metrics, margin trends, or year-on-year and quarter-on-quarter comparisons, the key takeaway for investors is the explicit quantum of the dividend at Rs 5 per share and its potential to enhance overall shareholder value through regular income. There is no information on whether this dividend is interim or final, nor on record date, payout timeline, or any associated corporate actions, so those aspects remain unverified based on the current context. No street expectations, analyst estimates, or formal guidance have been referenced, and there is also no data on immediate market reaction, including stock price movement or changes in volumes following the dividend news.
Given the limited but clear information, this development can be viewed primarily as a corporate action that underscores the company’s willingness to share profits with shareholders. Investors and market participants would typically monitor subsequent regulatory filings and detailed result disclosures for a fuller understanding of the company’s earnings trajectory, margin profile, and future dividend policy, but such details are not part of the current verified input.
Dr Lal Pathlabs posts strong Q1 FY earnings with robust revenue growth
ResultLALPATHLAB24 Jul 2026
Dr Lal Pathlabs reported a healthy year-on-year improvement in its quarterly performance, led primarily by solid revenue growth. For the reported Q1 period, the company posted revenue of about Rs 800 crores, compared with Rs 670 crores in the corresponding quarter last year. This implies a strong expansion in top line on a year-on-year basis, indicating improved business volumes, better realisation, or a combination of both in its diagnostics and related services portfolio. The sizeable increase in revenue underscores sustained demand for diagnostic testing and the company’s ability to capture that demand across its network.
The data provided focuses only on revenue and its year-on-year comparison. There is no information in the given context about EBITDA, PAT, operating margins, net margins, or quarter-on-quarter performance, so those aspects cannot be commented on. Similarly, there is no reference to management commentary, forward guidance, or any specific strategic initiatives in this update. Consensus or street expectations are also not mentioned, so it is not possible to assess whether the reported numbers were above, in line with, or below market expectations.
No details have been provided on the immediate equity market reaction, including intraday stock price movement on NSE or BSE, changes in trading volumes, or shifts in valuation multiples following the result. However, within the limited data set, the notable takeaway is the strong year-on-year revenue growth from Rs 670 crores to Rs 800 crores, which reflects a positive operational trajectory for Dr Lal Pathlabs in the latest reported quarter, even though profitability and margin trends remain undisclosed in this specific context.
Dr Lal Pathlabs reports higher quarterly EBITDA and improved margin
ResultLALPATHLAB24 Jul 2026
Dr Lal Pathlabs reported Q1 EBITDA of Rs 250.00 crores, up from Rs 192.00 crores a year earlier, reflecting a YoY increase in operating earnings.
EBITDA margin improved to 31.0% from 28.7% in the same quarter last year, indicating better operating efficiency. The provided update does not include revenue, PAT, QoQ comparisons, or management commentary, so those details are not included here.
Dr Lal Pathlabs posts strong Q1 FY earnings with robust profit growth
ResultLALPATHLAB24 Jul 2026
Dr Lal Pathlabs reported a solid improvement in profitability for the latest reported quarter, with consolidated net profit rising to Rs 170 crores compared with Rs 130 crores in the same quarter last year on a year-on-year basis. This represents a healthy expansion in profit levels, indicating better earnings performance versus the previous year. The numbers suggest that the company has managed to grow its bottom line meaningfully despite operating in a competitive diagnostics market.
While detailed revenue, EBITDA, and margin metrics are not provided in the available context, the sharp increase in consolidated net profit on a year-on-year basis implies either higher operating leverage, improved cost efficiencies, better test mix, or a combination of these factors. Investors and analysts would typically interpret such profit growth as a positive indicator of operating performance, especially if it is supported by stable or improving margins and sustainable volume trends in diagnostic services. In the absence of additional disclosures, there is no visibility on quarter-on-quarter trends, specific revenue growth rates, or detailed margin movement.
No information is available in the given text regarding market expectations, consensus estimates, or management commentary, so it is not possible to assess whether the reported profit beat or missed street forecasts. Similarly, the immediate stock price reaction, impact on valuations, or any guidance for subsequent quarters is not mentioned. Based solely on the disclosed increase in consolidated net profit from Rs 130 crores to Rs 170 crores on a year-on-year basis, the news flow is directionally positive for Dr Lal Pathlabs, even though the broader financial and market context is not fully detailed in the provided data.
Dr Lal PathLabs sees Rs 25.89 crore NSE block trade in equity shares
Block DealLALPATHLAB3 Jul 2026
Dr Lal PathLabs Limited witnessed a notable block trade on the NSE, with shares of the company changing hands in a single transaction worth approximately Rs 25.89 crores. The deal involved about 1.59 lakh shares of LALPATHLAB, executed at a price of around Rs 1,626.6 per share. This type of block trade typically reflects activity by institutional investors or large shareholders transacting off the regular market order book to reduce visible market impact and obtain negotiated pricing. However, the identities of the buyer and seller have not been disclosed in the available information, and there is no confirmed detail on whether the trade represents promoter, institutional, or fund-level activity, nor any explicit indication of a strategic change in shareholding.
Based on recent price data around Rs 1,620–1,650 per share for Dr Lal PathLabs on the NSE, the negotiated block price of Rs 1,626.6 appears broadly in line with prevailing market levels, suggesting the transaction was likely executed at a marginal discount or near the average trading price for the day rather than at a significant premium. The trade size, while sizeable in rupee terms, is relatively routine for a mid-to-large cap diagnostic services company and does not on its own imply a major change in control or governance. There is no verifiable information yet on any follow-through move in the stock price specifically attributable to this block deal, and no confirmed regulatory filing pointing to a material shift in shareholding pattern associated with this transaction. Overall, the event reflects ongoing liquidity and institutional interest in Dr Lal PathLabs, but with limited disclosed detail on counterparties or strategic intent, it currently appears as a standard secondary market block trade.
Dr Lal PathLabs board to consider Q1 FY27 results on July 24
Stock NewsLALPATHLAB29 Jun 2026
Dr Lal PathLabs, a leading diagnostic services provider listed on the NSE and BSE, has notified that its board of directors will meet on July 24 to consider and approve the financial results for the first quarter of FY27. The scheduled board meeting to review Q1 numbers is a routine but important corporate event, as it will provide updated visibility on the company’s revenue growth, margin trajectory, and earnings performance in the early part of the new financial year. The company has also indicated a corresponding trading window closure period around the board meeting date in line with corporate governance and insider trading regulations, reinforcing adherence to SEBI norms on handling unpublished price sensitive information.
Investors and market participants will closely track the upcoming Q1 FY27 results, given the company’s recent trend of strong revenue growth and improving earnings, as reflected in prior quarterly performance. This board meeting could influence near-term sentiment in the stock once the results are announced, particularly if there are notable changes in patient volumes, realizations, operating leverage, or any updates on network expansion and capital allocation. As of now, there is no indication of concurrent corporate actions such as dividends, rights issue, buyback, large capex announcement, or management change linked specifically to this meeting, and the development primarily relates to the financial disclosures for the quarter. In the absence of any pre-guidance on earnings or explicit commentary on regulatory actions, the event is best characterised as a standard financial results consideration, with market reaction likely to depend on the actual numbers and commentary shared on July 24.
Dr. Lal Pathlabs incorporates wholly owned subsidiary in Dubai
Stock NewsLALPATHLAB13 Jun 2026
The WOS intends to strategically invest in Diagnostics and allied activities
Block deal in Dr. Lal Path Labs shares on NSE worth Rs 20.56 crores
Block DealLALPATHLAB26 May 2026
Dr. Lal Path Labs Ltd. witnessed a notable block trade on the NSE, indicating institutional or large-investor interest in the counter. The transaction involved approximately 126,673 shares changing hands in a single or limited set of large trades. The total deal value was around Rs 20.56 crores, highlighting a reasonably sized secondary market transaction for the stock. The block deal was executed at a price of Rs 1,622.90 per share, providing a clear reference level for market participants tracking volumes and price action in the stock. Details on the specific identities of the buyer and seller, including whether they belong to the promoter group, strategic investors, domestic or foreign institutions, or other large shareholders, were not disclosed in the provided context. As a result, the precise nature of the stake reallocation and whether it reflects entry, exit, or rebalancing activity by any particular category of investor cannot be ascertained from this information alone. The approximate share quantity suggests only a fractional change in overall shareholding relative to the company’s total equity base, implying that the transaction represents a portfolio-level move rather than a change in control. No data is available in the context regarding the prevailing market price at the time of the trade, so any premium or discount versus the last traded price or volume-weighted average price cannot be computed. Similarly, the immediate follow-through in terms of intraday or subsequent stock price movement post the block deal is not specified. Nevertheless, such trades are typically monitored by market participants for potential signals on large investor sentiment and supply-demand dynamics in the stock.

